NCT00360438View on ClinicalTrials.gov

Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
LeukemiaLymphomaTumor Lysis Syndrome
Interventions
DRUG

Rasburicase

0.15mg/kg intravenously over 30 minutes once per day for 5 consecutive days.

Trial Locations (1)

77030

The University of Texas M.D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER